Maven Securities LTD Has $738,000 Holdings in Liquidia Technologies, Inc. $LQDA

Key Points

• Maven Securities LTD has reduced its stake in Liquidia Technologies, Inc. by 75% after selling 150,000 shares, now holding only 50,000 shares valued at approximately $738,000.
• Multiple institutional investors have increased their stakes in Liquidia Technologies, with Invesco Ltd. growing its ownership by an impressive 2,675% during the fourth quarter.
• Recent analyst ratings for Liquidia Technologies highlight a positive outlook, with price target increases from Raymond James to $41.00, indicating strong buy sentiment across multiple firms.

Maven Securities LTD trimmed its stake in Liquidia Technologies, Inc. (NASDAQ:LQDA - Free Report) by 75.0% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 50,000 shares of the company's stock after selling 150,000 shares during the period. Maven Securities LTD owned 0.06% of Liquidia Technologies worth $738,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in LQDA. Invesco Ltd. raised its stake in shares of Liquidia Technologies by 2,675.0% in the 4th quarter. Invesco Ltd. now owns 700,171 shares of the company's stock valued at $8,234,000 after acquiring an additional 674,940 shares in the last quarter. Janus Henderson Group PLC boosted its stake in Liquidia Technologies by 1,484.5% during the 4th quarter. Janus Henderson Group PLC now owns 535,552 shares of the company's stock valued at $6,293,000 after purchasing an additional 501,752 shares during the period. Eversept Partners LP boosted its stake in Liquidia Technologies by 314.1% during the 4th quarter. Eversept Partners LP now owns 571,305 shares of the company's stock valued at $6,719,000 after purchasing an additional 433,356 shares during the period. Tang Capital Management LLC increased its position in Liquidia Technologies by 37.5% in the 4th quarter. Tang Capital Management LLC now owns 1,100,000 shares of the company's stock worth $12,936,000 after buying an additional 300,000 shares during the period. Finally, Whitefort Capital Management LP increased its position in Liquidia Technologies by 16.8% in the 4th quarter. Whitefort Capital Management LP now owns 1,987,245 shares of the company's stock worth $23,370,000 after buying an additional 285,220 shares during the period. 64.54% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have commented on LQDA shares. Raymond James Financial lifted their price target on Liquidia Technologies from $33.00 to $41.00 and gave the stock a "strong-buy" rating in a research report on Wednesday, August 13th. Oppenheimer set a $13.00 price target on Liquidia Technologies and gave the stock an "underperform" rating in a research report on Monday, May 19th. Bank of America dropped their price target on Liquidia Technologies from $25.00 to $23.00 and set a "buy" rating on the stock in a research report on Wednesday, June 11th. Needham & Company LLC lifted their price target on Liquidia Technologies from $32.00 to $36.00 and gave the stock a "buy" rating in a research report on Tuesday, August 12th. Finally, HC Wainwright lifted their price target on Liquidia Technologies from $29.00 to $35.00 and gave the stock a "buy" rating in a research report on Wednesday, May 28th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $32.11.

Insiders Place Their Bets

In related news, insider Jason Adair sold 2,576 shares of the business's stock in a transaction on Monday, July 14th. The stock was sold at an average price of $14.28, for a total value of $36,785.28. Following the sale, the insider owned 193,634 shares of the company's stock, valued at $2,765,093.52. The trade was a 1.31% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Sarah Krepp sold 2,673 shares of the business's stock in a transaction on Monday, July 14th. The shares were sold at an average price of $14.28, for a total value of $38,170.44. Following the completion of the sale, the insider directly owned 142,499 shares in the company, valued at approximately $2,034,885.72. This represents a 1.84% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 90,277 shares of company stock worth $1,469,392 over the last quarter. Corporate insiders own 26.50% of the company's stock.

Liquidia Technologies Price Performance

LQDA traded down $0.46 during midday trading on Friday, reaching $26.84. 2,601,589 shares of the company's stock were exchanged, compared to its average volume of 3,258,115. The company has a quick ratio of 2.41, a current ratio of 2.49 and a debt-to-equity ratio of 9.84. The business has a 50-day simple moving average of $17.51 and a two-hundred day simple moving average of $15.96. The firm has a market capitalization of $2.31 billion, a price-to-earnings ratio of -15.79 and a beta of 0.14. Liquidia Technologies, Inc. has a one year low of $8.75 and a one year high of $28.00.

Liquidia Technologies (NASDAQ:LQDA - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.06). Liquidia Technologies had a negative net margin of 732.17% and a negative return on equity of 232.96%. The company had revenue of $8.84 million during the quarter, compared to the consensus estimate of $3.90 million. The company's quarterly revenue was up 141.5% on a year-over-year basis. As a group, research analysts predict that Liquidia Technologies, Inc. will post -1.51 EPS for the current year.

Liquidia Technologies Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).